VVOS (Vivos Therapeutics) Total Enterprise Value
The growth of Vivos Therapeutics (VVOS) relies on the increasing number of dental practices implementing their IT solutions to combat apnea, while maintaining stable control over insurance reimbursements. Delivery efficiency is guaranteed via direct courier shipping of equipment to clinics. The asset value tracked on this chart is 15.77, highlighting the business's scalability potential through automated splint selection and high-margin mass production of devices.
Financial and market metric breakdowns for Vivos Therapeutics (VVOS)
Developing devices for the treatment of apnea requires significant expenditures for patient acquisition and clinical validation for Vivos Therapeutics (VVOS). Enterprise value combines market capitalization with net debt, excluding cash. This metric determines the actual investment required for a full buyout of the business. Investors must consider that an increase in valuation may be driven by the debt load. The historical enterprise value trend visualizes this dynamic.